CAR-T Cells Can Target Circulating TNF to Product Lasting Control of Autoimmune Conditions

The challenge inherent in present approaches to reduce unwanted inflammation and immune activation, such as by targeting circulating tumor necrosis factor (TNF) with monoclonal antibodies in the context of autoimmune conditions, is that this signaling is also used in the normal, desirable immune response. Suppression thus has side-effects on immune competence. Nonetheless, researchers continue to...

Raccontata dafightaging.org